Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

Cancer. 1991 Jul 15;68(2):269-71. doi: 10.1002/1097-0142(19910715)68:2<269::aid-cncr2820680209>;2-o.


One hundred five patients with Stage III or IV epithelial ovarian cancer whose disease had persisted or recurred after primary surgery and first-line chemotherapy were given tamoxifen (20 mg orally twice daily) and evaluated for response. Eighteen percent of the patients responded: 10% demonstrated a complete response (CR) and 8% showed a partial response (PR). Thirty-eight percent of the patients had short-term disease stabilization. CR had a median duration of 7.5 months, with the longest lasting 17 months. For patients with PR or stable disease, the median duration of response was 3 months (maximum duration, 9 months). When estrogen receptors of tumor tissue from patients demonstrating CR were evaluated, eight of nine (89%) had elevated estrogen receptor levels. This contrasts with patients who had stable or progressive disease as only 59% of them had measurable estrogen receptors (P = 0.16).

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Carcinoma / chemistry
  • Carcinoma / drug therapy*
  • Carcinoma / pathology
  • Female
  • Humans
  • Neoplasm Proteins / analysis
  • Neoplasm Staging
  • Ovarian Neoplasms / chemistry
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / pathology
  • Phosphoproteins / analysis
  • Prospective Studies
  • Receptors, Estrogen / analysis
  • Remission Induction
  • Tamoxifen / therapeutic use*


  • Neoplasm Proteins
  • Phosphoproteins
  • Receptors, Estrogen
  • Tamoxifen